42 completed, 12 recruiting, 12 terminated, 9 unknown. 76 Phase 1, 22 Phase 2, 4 Phase 3, 1 Phase 4.
Follow Advanced Malignancies: new trials by email Literature Review of Advanced Malignancies trials Research Report on Advanced Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Study of HCB303 in Participants With Advanced Malignancies HCB303 - Advanced Malignancies | Phase 1 | Not yet recruiting | FBD Biologics Limited | 150 | 2027-02-28 | 2026-10-05 |
| A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors TQB6426 for Injection - Advanced Malignancies | Phase 1 | Recruiting | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | 145 | 2026-08-25 | 2026-09-15 |
| An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers PF-07994525, Midazolam - Advanced Malignancies, Advanced Cancer | Phase 1 | Recruiting | Pfizer | 120 | 2026-07-01 | 2026-10-13 |
| A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies pelabresib, repaglinide, midazolam - Advanced Malignancies | Phase 1 | Recruiting | Novartis Pharmaceuticals | 24 | 2026-06-12 | 2026-10-09 |
| Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies Pembrolizumab, PM54 - Advanced Malignancies | Phase 1 / Phase 2 | Recruiting | PharmaMar | 119 | 2026-05-21 | 2026-10-13 |
| Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies RP-001 - Advanced Malignancies, Oncology | Phase 1 / Phase 2 | Not yet recruiting | Recurv Pharma Inc | 66 | 2026-04-23 | 2026-03-31 |
| Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Pralsetinib, CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive - NSCLC (Non-small Cell Lung Cancer), Thyroid Cancer | Phase 4 | Recruiting | Rigel Pharmaceuticals | 12 | 2026-03-04 | 2026-08-10 |
| A Study of BR111 in Patients With Advanced Malignancies BR111 for Injection - Advanced Malignancies | Phase 1 | Recruiting | BioRay Pharmaceutical Co., Ltd. | 166 | 2025-04-24 | 2025-11-21 |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Pelabresib - Hematologic Malignancy, Solid Tumor | Phase 3 | Recruiting | Novartis Pharmaceuticals | 50 | 2024-08-13 | 2026-06-11 |
| A Study of IBI363 in Subjects With Advanced Malignancies IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC - Advanced Malignancies | Phase 1 | Recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 556 | 2024-06-15 | 2024-07-18 |
| Phase I Study of XZ120 in Malignant Tumors XZ120 injection - Advanced Malignancies | Phase 1 | Not yet recruiting | Shandong New Time Pharmaceutical Co., LTD | 123 | 2024-02-01 | 2024-01-16 |
| Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers AB598, Zimberelimab, Fluorouracil - Advanced Cancer, Advanced Malignancies | Phase 1 | Active not recruiting | Arcus Biosciences, Inc. | 40 | 2023-10-13 | 2026-09-29 |
| A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies BRY812 for injection - Advanced Malignancies | Phase 1 | Recruiting | BioRay Pharmaceutical Co., Ltd. | 164 | 2023-10-10 | 2025-12-30 |
| Phase I/II Clinical Study of 1A46 Drug Substance 1A46 Drug Substance - Advanced Malignancies | Phase 1 | Terminated | BioRay Pharmaceutical Co., Ltd. | 4 | 2023-09-12 | 2025-02-19 |
| A Study of IBI363 in Combination With Bevacizumab or Furuitinib in Subjects With Advanced Colorectal Cancer IBI363 combined with Bevacizumab, IBI363 + Furuitinib - Advanced Malignancies | Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 260 | 2023-07-28 | 2025-02-12 |
| A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer TQB2930 for injection, Paclitaxel for injection (albumin-bound), TQB3616 capsule - Metastatic Breast Cancer, Recurrent Breast Cancer | Phase 1 / Phase 2 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 154 | 2023-04-13 | 2024-03-12 |
| INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma INCAGN01876, retifanlimab - Metastatic Head and Neck Squamous Cell Carcinoma, Advanced Malignancies | Phase 2 | Withdrawn | Incyte Biosciences International Sàrl | 2023-03-01 | 2023-09-15 | |
| Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies INCA32459-101 - Advanced Malignancies | Phase 1 | Completed | Incyte Corporation | 46 | 2023-01-05 | 2025-11-03 |
| Clinical Study of BR105 Injection BR105 injection - Advanced Malignancies | Phase 1 | Terminated | BioRay Pharmaceutical Co., Ltd. | 31 | 2022-04-19 | 2026-03-17 |
| IBI397 or Combination Therapies in Patients With Advanced Malignancies IBI397, IBI397+Sintilimab, IBI397+Rituximab - Advanced Malignancies | Phase 1 | Withdrawn | Innovent Biologics (Suzhou) Co. Ltd. | 2022-04-14 | 2023-09-05 |
Showing 20 of 85. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Neoplasms (11) · Melanoma (9) · Ovarian Neoplasms (8) · Carcinoma, Renal Cell (7) · Neoplasm Metastasis (7) · Squamous Cell Carcinoma of Head and Neck (6) · Esophageal Neoplasms (5) · Stomach Neoplasms (5) · Adenocarcinoma (4) · Carcinoma, Hepatocellular (4) · Carcinoma, Transitional Cell (4) · Mesothelioma (4) · Small Cell Lung Carcinoma (4) · Triple Negative Breast Neoplasms (4)
Neoplasms (25) · Neoplasms by Site (23) · Neoplasms by Histologic Type (19) · Neoplasms, Glandular and Epithelial (15) · Bronchial Neoplasms (13) · Carcinoma, Bronchogenic (13) · Lung Diseases (13) · Respiratory Tract Diseases (13) · Respiratory Tract Neoplasms (13) · Thoracic Neoplasms (13) · Carcinoma (11) · Lung Neoplasms (11) · Skin Diseases (11) · Skin and Connective Tissue Diseases (11) · Endocrine Gland Neoplasms (10)
pembrolizumab (7) · Injections (5) · epothilone B (5) · Paclitaxel (4) · Capecitabine (3) · Gemcitabine (3) · Ipilimumab (3) · Nivolumab (3) · Pemetrexed (3) · cemiplimab (3) · parsaclisib (3) · Azacitidine (2) · Bevacizumab (2) · Drug Therapy (2) · MLN 8237 (2)
Novartis Pharmaceuticals (9) · Innovent Biologics (Suzhou) Co. Ltd. (8) · Incyte Biosciences International Sàrl (6) · Incyte Corporation (6) · BioRay Pharmaceutical Co., Ltd. (4) · Jiangsu HengRui Medicine Co., Ltd. (3) · Millennium Pharmaceuticals, Inc. (3) · Pfizer (3) · Regeneron Pharmaceuticals (3) · Ariad Pharmaceuticals (2) · Beijing Mabworks Biotech Co., Ltd. (2) · Bristol-Myers Squibb (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Mirati Therapeutics Inc. (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)
United States (49) · China (25) · Spain (15) · Italy (8) · Japan (8) · Australia (7) · United Kingdom (7) · Taiwan (6) · Canada (5) · South Korea (5) · Belgium (4) · Denmark (4) · France (4) · Netherlands (4) · Russia (3)
John E. Janik, MD (3) · Andres McAllister, PhD (1) · Avi Retter, M.D. (1) · Charles W. Finn, PhD (1) · Divis K Khaira, M.D. (1) · Dr Timothy Yap (1) · Ekaterine Asatiani, M.D. (1) · Hanneke Wilmink, MD, PhD (1) · Howard A Burris, III, M.D. (1) · Huajun Jin (1)
PMID 24739759, PMID 26189934, PMID 26966027, PMID 27879972, PMID 28501139, PMID 29863979, PMID 30280657, PMID 31439037, PMID 31851518, PMID 32554615, PMID 32780660, PMID 33146741, PMID 33831732, PMID 33883177, PMID 33942954, PMID 36316061, PMID 36797744, PMID 39209782, PMID 39281971, PMID 39707229, PMID 39736787, PMID 39816916, PMID 40318595, PMID 40711469, PMID 41410381, PMID 41591537, PMID 41740899
2023 (4), 2015 (3), 2016 (3), 2025 (3), 2018 (1), 2019 (1)